Fig. 1From: The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysisForest plots of the incidence of TRAEs for combined immunotherapy (anti-PD-1/PD-L1 and anti-CTLA-4). a any grade TRAEs, b grade 3 or higher TRAEsBack to article page